Legend Biotech Statistics
Legend Biotech (9LB) Stock Statistics & Valuation Metrics
Total Valuation
Legend Biotech has a market cap or net worth of EUR 4.04B. The enterprise value is EUR 4.91B.
- Market Cap
- EUR 4.04B
- Enterprise Value
- EUR 4.91B
Share Statistics
Legend Biotech has 194,488,420 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 194,488,420
- Owned by Insiders
- 0.93%
- Owned by Institutions
- 20.27%
Financial Efficiency
Legend Biotech’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -9.59%.
- Return on Equity (ROE)
- -0.30
- Return on Assets (ROA)
- -0.17
- Return on Invested Capital (ROIC)
- -9.59%
- Return on Capital Employed (ROCE)
- -0.12
- Revenue Per Employee
- 321.53K
- Profits Per Employee
- -92.75K
- Employee Count
- 3,200
- Asset Turnover
- 0.59
- Inventory Turnover
- 12.75
Valuation Ratios
The current PE Ratio of Legend Biotech is -48.58. Legend Biotech’s PEG ratio is -0.59.
- PE Ratio
- -48.58
- PS Ratio
- 3.53
- PB Ratio
- 3.69
- Price to FCF
- -17.58
- Price to Operating Cash Flow
- -24.81
- PEG Ratio
- -0.59
Income Statement
In the last 12 months, Legend Biotech had revenue of 1.03B and earned -296.80M in profits. Earnings per share was -1.60.
- Revenue
- 1.03B
- Gross Profit
- 620.80M
- Operating Income
- -136.50M
- Pretax Income
- -282.60M
- Net Income
- -296.80M
- EBITDA
- -232.30M
- Earnings Per Share (EPS)
- -1.60
Cash Flow
In the last 12 months, operating cash flow was -183.10M and capital expenditures -72.52M, giving a free cash flow of -255.58M billion.
- Operating Cash Flow
- -183.10M
- Free Cash Flow
- -255.58M
- Free Cash Flow per Share
- -1.37
Dividends & Yields
Legend Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -5.68%
- Earnings Yield
- -2.02%
Stock Price Statistics
- Beta
- 0.61
- 52-Week Price Change
- -25.00%
- 50-Day Moving Average
- 17.29
- 200-Day Moving Average
- 19.21
- Relative Strength Index (RSI)
- 67.68
- Average Volume (3m)
- 244
Important Dates
Legend Biotech upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Mar 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Legend Biotech as a current ratio of 1.96, with Debt / Equity ratio of 41.28%
- Current Ratio
- 1.96
- Quick Ratio
- 1.91
- Debt to Market Cap
- 0.08
- Net Debt to EBITDA
- 2.10
- Interest Coverage Ratio
- -6.38
Taxes
In the past 12 months, Legend Biotech has paid 14.20M in taxes.
- Income Tax
- 14.20M
- Effective Tax Rate
- -0.05
Enterprise Valuation
Legend Biotech EV to EBITDA ratio is 1994.77, with an EV/FCF ratio of -16.05.
- EV to Sales
- 3.23
- EV to EBITDA
- 1994.77
- EV to Free Cash Flow
- -16.05
- EV to Operating Cash Flow
- -22.40
Balance Sheet
Legend Biotech has EUR 964.63M in cash and marketable securities with EUR 278.21M in debt, giving a net cash position of EUR 686.42M billion.
- Cash & Marketable Securities
- EUR 964.63M
- Total Debt
- EUR 278.21M
- Net Cash
- EUR 686.42M
- Net Cash Per Share
- EUR 3.53
- Tangible Book Value Per Share
- EUR 6.58
Margins
Gross margin is 56.58%, with operating margin of -4.42%, and net profit margin of -7.21%.
- Gross Margin
- 56.58%
- Operating Margin
- -4.42%
- Pretax Margin
- -4.43%
- Net Profit Margin
- -7.21%
- EBITDA Margin
- 0.16%
- EBIT Margin
- -3.39%
Analyst Forecast
The average price target for Legend Biotech is EUR 41.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 41.00
- Price Target Upside
- 95.22% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 10
- Revenue Growth Forecast
- 49.14%
- EPS Growth Forecast
- 73.59%
Scores
- Smart Score
- 8
- AI Score
- ―
